1. The participants recognized the worldwide absence of any systematized pharmacologically-assisted psychotherapy research program involving both pre-clinical and clinical investigations and supported increasing the research effort.
2. Psychiatrists from the US and the USSR agreed to begin designing a protocol for the investigation of the use of MDMA in the psychotherapeutic treatment of patients with terminal illness. Their intention is to conduct the identical experiment in both countries in order to increase statistical validity and generalizability of the results.
3. US neurotoxicity researchers tentatively agreed that the neurotoxic risk to patients with terminal illness is balanced by potential psychotherapeutic benefits. If the protocol is rigorously designed to provide additional data about both neurotoxic risk and therapeutic efficacy, they may support the protocol before the FDA.
4. MAPS agreed to help assemble a small group of distinguished U.S. scientists and researchers to review, critique and endorse protocols prior to FDA submission.